Agreed!; ). I only mentioned ADCs really in light of replacing chemo/rad which was utilized in the trial as a preparation (creation of cancer cell damage to expose targets) for L mediated immune response. Chemo/rad creates more debilitating systemic side effects than some very highly targeted ADCs. With this in mind some big pharmas are likely thinking a few ADCs might be good candidates with regard to post surgical treatment of the cancer that remains as an alternate environmental prep for L trained T-cells and other immune system responders. Direct does not really need any special prep other than perhaps help with initial tumor environment to speed up response when initially administered. This potentially could come from ADCs but more than likely even they are not needed because of the Rosewell Parks tech which will help improve outcomes with Direct even more than what was seen in the Phase 1 safety trial. Bottom line is that yes, big pharma is pushing for relevance in the future of cancer patient care and I have said this time was coming almost from my first posts on Seeking Alpha back in the day ; ). Best wishes.
Market Data 
Markets 
AI
